Medical management for chronic atherosclerotic peripheral arterial disease

Drugs

Volumn 72, Issue 16, 2012, Pages 2073-2085

  Ali, Farzana Nawaz ^a   Carman, Teresa L ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arginine; Aspirin; Atorvastatin; Beraprost; Cilostazol; Ciprostene; Clopidogrel; Ecraprost; Ezetimibesimvastatin; Iloprost; Intermittent claudication; Ischaemia; K 134; Parogrelil; Pentoxifylline; Peripheral arterial disorders; Peripheral vascular disorders; Propionyl carnitine; Ranolazine; Simvastatin; Sodium crocetinate; Vorapaxar.

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; ATORVASTATIN; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; FIBROBLAST GROWTH FACTOR 2; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; NICOTINE; PENTOXIFYLLINE; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; RAMIPRIL; RANOLAZINE; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VORAPAXAR;

ANGINA PECTORIS; ANGIOGENESIS; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CRITICAL LIMB ISCHEMIA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; FLUSHING; GASTROINTESTINAL SYMPTOM; GINKGO BILOBA; HEART PALPITATION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SMOKING CESSATION; SORE THROAT; TOBACCO DEPENDENCE;

ATHEROSCLEROSIS; EXERCISE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; ISCHEMIA; LOWER EXTREMITY; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VASCULAR SURGICAL PROCEDURES; VASODILATOR AGENTS;

EID: 84867696638     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11640810-000000000-00000     Document Type: Review

References (80)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006; 113: e463-654
2. Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med 2007 Apr; 32 (4): 328-33
3. Cimminiello C, Kownator S, Wautrecht JC, et al. The PANDORA study: peripheral arterial disease in patients with non-high cardiovascular risk. Intern Emerg Med 2011 Dec; 6 (6): 509-19
4. Dhangana R, Murphy TP, Coll JR, et al. Prevalence of abnormal ankle-brachial index among individuals with low or intermediate Framingham Risk Scores. J Vasc Interv Radiol 2011 Aug; 22 (8): 1077-82
5. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 1999 Feb; 159 (4): 387-92
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002 Dec 17; 106 (25): 3143-421
7. Li X, Luo Y, Xu Y, et al. Relationship of ankle-brachial index with all-cause mortality and cardiovascular mortality after a 3-year follow-up: the China ankle-brachial index cohort study. J Hum Hypertens 2010 Feb; 24 (2): 111-6
8. Sutton-Tyrrell K, Venkitachalam L, Kanaya AM, et al. Relationship of ankle blood pressures to cardiovascular events in older adults. Stroke 2008 Mar; 39 (3): 863-9
9. Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006 Mar 21; 47 (6): 1182-7
10. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on prgctice Guidelines. Circulation 2011 Nov 1; 124 (18): 2020-45
11. Carman TL, Fernandez Jr BB. Contemporary management of peripheral arterial disease: II. Improving walking distance and quality of life. Cleve Clin J Med 2006 Oct; 73 Suppl. 4: S38-44
12. Bianchi C, Montalvo V, Ou HW et al. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 2007 Mar; 21 (2): 163-6
13. Rehring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005 May; 41 (5): 816-22
14. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009 May 13; 301 (18): 1909-19
15. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherosclerotic events. N Engl J Med 2012 Apr 12; 366 (15): 1404-13
16. Hennrikus D, Joseph A, Lando H, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol 2010 Dec 14; 56 (25): 2105-12
17. Chi YW, Lavie CJ, Milani RV, et al. Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag 2008 Dec; 4 (6): 1197-203
18. Rizzo M, Corrado E, Patti AM, et al. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011 Mar; 12 (4): 647-55
19. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37 Suppl. 2: 1-11
20. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003 Oct; 38 (4): 710-3
21. Kim JS, Lee KS, Kim YI, et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004 Aug; 11 (6): 600-2
22. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998 Feb; 27 (2): 267-74
23. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, doubleblind trial. Circulation 1998 Aug 18; 98 (7): 678-86
24. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999 Sep 27; 159 (17): 2041-50
25. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000 Nov; 109 (7): 523-30
26. Mohler 3rd ER, Beebe HG, Salles-Cuhna S, et al. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc Med 2001; 6 (3): 151-6
27. Strandness Jr DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg 2002 Mar-Apr; 36 (2): 83-91
28. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008 Feb; 47 (2): 330-6
29. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002 Dec 15; 90 (12): 1314-9
30. Pande RL, Hiatt WR, Zhang P, et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010 Jun; 15 (3): 181-8
31. Strano A, Davi G, Avellone G, et al. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984 Jul; 35 (7): 459-66
32. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987 Jul; 34 (1): 50-97
33. Gallus AS, Gleadow F, Dupont P, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust N Z J Med 1985 Aug; 15 (4): 402-9
34. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. N Z Med J 1987 Jul 22; 100 (828): 445-7
35. De Sanctis MT, Cesarone MR, Belcaro G, et al. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial-walking distance and microcirculation. Angiology 2002 Jan-Feb; 53 Suppl. 1: S7-12
36. Cesarone MR, Belcaro G, Nicolaides AN, et al. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Angiology 2002 Jan-Feb; 53 Suppl. 1: S1-5
37. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996 Oct 15; 155 (8): 1053-9
38. Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline, and inositol nicotinate for the treatment of intermittent claudication in people with peripheral artery disease. Health Technol Assess 2010 Dec; 15 (40): 1-210
39. Mohler 3rd ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003 Sep 23; 108 (12): 1481-6
40. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003 Apr 1; 114 (5): 359-64
41. West AM, Anderson JD, Epstein FH, et al. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol 2011 Aug 30; 58 (10): 1068-76
42. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004 Jan; 25 (1): 17-24
43. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006 May 2; 144 (9): 660-4
44. Shahin Y, Mazari F, Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011; 9 (3): 209-13
45. Creager MA, Pande RL, Hiatt WR. A randomized trial of iloprost in patients with intermittent claudication. Vasc Med 2008 Feb; 13 (1): 5-13
46. Matsumoto T, Iwasa K, Kyuragi R, et al. The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. Int Angiol 2010 Apr; 29 (2 Suppl.): 49-54
47. Mohler 3rd ER, Hiatt WR, Olin JW, et al. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003 May 21; 41 (10): 1679-86
48. Barker GA, Green S, Askew CD, et al. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc 2001 Sep; 33 (9): 1415-22
49. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999 Nov 1; 34 (5): 1618-24
50. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001 Jun 1; 110 (8): 616-22
51. Hiatt WR, Creager MA, Amato A, et al. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. J Cardiopulm Rehabil Prev 2011 Mar-Apr; 31 (2): 125-32
52. Oka RK, Szuba A, Giacomini JC, et al. A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease. Vasc Med 2005 Nov; 10 (4): 265-74
53. Wilson AM, Harada R, Nair N, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007 Jul 10; 116 (2): 188-95
54. Gardner CD, Taylor-Piliae RE, Kiazand A, et al. Effect of Ginkgo biloba (EGb761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial. J Cardiopulm Rehabil Prev 2008 Jul-Aug; 28 (4): 258-65
55. Mughal NA, Russell DA, Ponnambalam S, et al. Gene therapy in the treatment of peripheral arterial disease. Br J Surg 2012 Jan; 99 (1): 6-15
56. Ghosh R, Walsh SR, Tang TY, et al. Gene therapy as a novel therapeutic option in the treatment of peripheral vascular disease: systematic review and meta-analysis. Int J Clin Pract 2008 Sep; 62 (9): 1383-90
57. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxiainducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011 Oct 18; 124 (16): 1765-73
58. Gainer JL. Trans-sodium crocetinate for treating hypoxia/ischemia. Expert Opin Investig Drugs 2008 Jun; 17 (6): 917-24
59. Mohler 3rd ER, Gainer JL, Whitten K, et al. Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication. Vasc Med 2011 Oct; 16 (5): 346-53
60. Ma A, Garland WT, Smith WB, et al. A pilot sudy of ranolazine in patients with intermittent claudication. Int Angiol 2006 Dec; 25 (4): 361-9
61. William Beaumont Hospitals. Supervised treadmill exercise and ranolazine for intermittent claudication of lower extremities (STERILE) [ClinicalTrials.gov identifier NCT00914316]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://www.clin caltrials.gov [Accessed 2012 Sep 20]
62. Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006 Dec 19; 48 (12): 2539-45
63. Brass EP, Cooper LT, Morgan RE, et al. A phase II doseranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg 2012 Feb; 55 (2): 381-9
64. Setacci C, de Donato G, Teraa M, et al. Chapter IV: treatment of critical limb ischemia. Eur J Endovasc Surg 2011 Dec; 42 Suppl. 2: S43-59
65. Colini BG, Carlizza A. Spinal cord stimulation: predictive parameters of outcomes in patients suffering from critical lower limb ischemia. A preliminary study. Neuromodulation 2011 Nov-Dec; 14 (6): 530-2; discussion 533
66. Sultan S, Hamada N, Soylu E et al. Sequential compression biomechanical device in patients with critical limb ischemia and nonreconstructable peripheral vascular disease. J Vasc Surg 2011 Aug; 54 (2): 440-6; discussion 446-447
67. Dean SM, Satiani B. Three cases of digital ischemia successfully treated with cilostazol. VascMed 2001 Nov; 6 (4): 245-8
68. Dean SM, Vaccaro PS. Successful pharmacologic treatment of lower extremity ulcerations in 5 patients with chronic critical limb ischemia. J Am Board Fam Pract 2002 Jan-Feb; 15 (1): 55-62
69. Miyashita Y, Saito S, Miyamoto A, et al. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 2011 Jan; 62 (1): 15-7
70. Soga Y, Iida O, Hirano K, et al. Impact of cilostazol after endovascular treatments for infrainguinal disease in patients with critical limb ischemia. J Vasc Surg 2011 Dec; 54 (6): 1659-67
71. No authors listed. Efficacy and clinical tolerability of parenteral pentoxifylline in the treatment of critical lower limb ischemia: a placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group. Int Angiol 1996 Mar; 15 (1): 75-80
72. No authors listed. Intravenous pentoxifylline for the treatment of chronic critical limb ischemia. The European Study Group. Eur J Vasc Endovasc Surg 1995 May; 9 (4): 426-36
73. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischemia. Cochrane Database Syst Rev 2010 Jan 20; (1): CD006544
74. Berman S, Quick R, Yoder P, et al. Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study. Vascular 2006 May-Jun; 14 (3): 142-8
75. Southern Arizona Vascular Institute. UT-15C SR in the treatment of critical limb ischemia [ClinicalTrials.gov identifier NCT00445159]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clincaltrials.gov [Accessed 2012 Sep 20]
76. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011 Feb; 53 (2): 445-53
77. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011 Feb1; 4 (1): 26-37
78. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011 Apr; 92 (1): 26-36
79. Powell RJ, Comerota AJ, Berceli SA, et al. Interim analysis results from RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in critical limb ischemia. J Vasc Surg 2011 Oct; 54 (4): 1032-41
80. Perin EC, Silva G, Gahremanpour A, et al. A randomized, controlled study of autologous therapy with bone marrowderived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011 Dec; 78 (7): 1060-7